Disease · MONDO_0044889
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Mosun-Pola vs Arm B: R-GemOx: deaths from any cause | 66 of 135 | 35 of 64 | 199 | NCT05171647 | Trial comparisons |
| Arm A: Mosun-Pola vs Arm B: R-GemOx: serious adverse events | 45 of 135 | 16 of 64 | 199 | NCT05171647 | Trial comparisons |
| Cohort A: Loncastuximab Tesirine + Rituximab (Lonca-R) vs Cohort B: Loncastuximab Tesirine + Rituximab (Lonca-R): Number of Participants With Confirmed Positive Anti-Drug Antibody (ADA) Response | 0 of 17 | 0 of 24 | 41 | NCT05144009 | Trial comparisons |
| Cohort A: Loncastuximab Tesirine + Rituximab (Lonca-R) vs Cohort B: Loncastuximab Tesirine + Rituximab (Lonca-R): deaths from any cause | 5 of 17 | 10 of 24 | 41 | NCT05144009 | Trial comparisons |
| Cohort A: Loncastuximab Tesirine + Rituximab (Lonca-R) vs Cohort B: Loncastuximab Tesirine + Rituximab (Lonca-R): serious adverse events | 13 of 17 | 16 of 24 | 41 | NCT05144009 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: Number of Deaths Due to Adverse Events (AEs) | 1 of 17 | 0 of 6 | 23 | NCT04313608 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: Number of Treatment Discontinuations Due to AE | 1 of 17 | 1 of 6 | 23 | NCT04313608 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: deaths from any cause | 1 of 17 | 0 of 6 | 23 | NCT04313608 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: serious adverse events | 12 of 17 | 4 of 6 | 23 | NCT04313608 | Trial comparisons |
| Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: Number of Participants With Dose Limiting-toxicity (DLT) | 2 of 5 | 1 of 3 | 8 | NCT04933617 | Trial comparisons |
Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 5 of 5 | 3 of 3 | 8 | NCT04933617 | Trial comparisons |
| Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: deaths from any cause | 5 of 5 | 0 of 3 | 8 | NCT04933617 | Trial comparisons |
| Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: serious adverse events | 2 of 5 | 0 of 3 | 8 | NCT04933617 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044889/comparisons